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reflects a preference on behalf of the decision maker. Reality does not always match 
the ideal of a fixed threshold.
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Objectives: South America (SA) is a continent with 400 million people and occu-
pies 12% of the world’s territory. It is composed by 12 countries and 6.75% of its 
population is below the poverty line, as defined by UN. The proper distribution of 
financial health resources, through an HTA process in public systems is potentially 
essential to improve the quality of health care expenditure. The objective of this 
study is to understand the incorporation process of new health technologies and 
compare the general health status in each country, regarding the Objectives of 
the Millennium (OM). MethOds: A public data collection was performed in offi-
cial sources linked to UN, to governments of SA and the Unión de las Naciones 
Suramericana (UNASUR). Results: The public health financing in SA countries 
was between 2.43% and 6.20% of the GDP. An HTA process in an institutionalized 
and specialized form is in place in only 3 countries (Argentina, Brazil and Peru). 
Bolivia, Chile, Colombia, Paraguay and Venezuela do not have a specialized HTA 
process and the other four countries have no HTA process at all. Regarding the OM 
the decrease in child mortality, increase in vaccination, increase in malaria and 
tuberculosis treatments are among the closest to be achieved in all countries. There 
is a linear positive correlation of OM with the Human Development Index and with 
the percentage of GDP invested in public health but not with having a HTA process 
in place. cOnclusiOn: At this moment, there is no evidence that an HTA process 
in place helps SA countries to achieve the OM.
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Objective: The Balduzzi law (189/2012) introduced several changes aimed at pro-
moting the country’s development through a higher level of health protection and 
at bridging the gap left by the rationing of health care resource from the Spending 
Review (135/2012). Reducing the time to drug market access is one of the main pur-
poses. The aim of the research is a critical analysis of this law to understand its actual 
and future impact on the health care scenario. MethOds: An evaluation of the laws 
issued in the last three years that aimed at regulating the drug market was carried out. 
To build a future scenario analysis, we focused our attention on the Balduzzi law and 
two of its articles (11 and 12) and on the new drugs approved by AIFA and commercial-
ized under the new regulation. Results: The changes that will have a major impact 
on the drug market are: the allocation of the medicines approved under centralized 
procedure in the non-negotiated C Class within 60 days from the publication in the 
Official Gazzette of the European Union and the direct placement of generics and bio-
similars in the reimbursement class of the originator without any price negotiation. As 
of now, a total number of 49 drugs have been included in the non-negotiated C Class, 
within this new group there are 15 first drug authorizations. cOnclusiOn: The new 
reform can be potentially an interesting innovation to speed up market access, though 
the impact of including new drugs in the C class (at patient charge) before the price 
negotiation is still under debate. The increased competitiveness coming from having 
a faster introduction in the market of generics/biosimilars could lead to important 
savings for the National Healthcare System over the next years.
PHP223
invesTing in euroPeAn HeAlTH r&D – A PATHwAy To susTAineD 
innovATion AnD sTronger econoMies
Pasmans R.1, Saka Ö1, Urbina-Valdespino E.1, Delwart V.2, Gijssels S.2
1Deloitte, Diegem, Belgium, 2Janssen Pharmaceutica NV, Bersee, Belgium
A large number of factors point to an unavoidable rise in health care expenditure to 
13%-18% of Europe’s GDP by 2030, even with policy interventions or budget caps that 
aim to counterbalance these pressures. This growth in health care costs need not be 
undesirable especially so when higher spending on health care leads to improved health 
care quality and life expectancy. Therefore, the challenge is not “how do we reverse the 
growth of health care costs?” but “how can we best deploy the increasing resources spent 
on health care to create optimal benefits for the European population?” Health R&D is 
the key to being able to respond to this dilemma. Increased investment in R&D leads to 
improved health outcomes, long term efficiency gains, better productivity and high eco-
nomic yields. However, the outlook for Europe is not as positive as it could be. Recently, 
there has been a stagnation or even decline in European private and public investment 
in R&D, which is in sharp contrast with the much higher investments in the US. Private 
biopharmaceutical investments in health R&D, which are double the size of public health 
R&D, in 2011 actually decreased in absolute terms. Public R&D investments declined or 
stagnated in most European countries and will be further under pressure in the near 
future due to public budget deficits. Janssen commissioned the Deloitte European Center 
on Health Economics and Outcomes Research to set out the arguments in support of 
increased investment in health R&D in Europe. The paper demonstrates that, even in 
times of austerity, policymakers need to prioritise approaches that will enhance public 
R&D investments and adopt strategies that produce incentives for private enterprises 
so that the current decline in private sector investment is halted.
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questions about priority and importance of certain outcome parameters like the 
thrombolysis rates vs. the independence of patients after 3 months. Finally, the com-
bination of MCDA and simulation modeling contributes to a transparent analytic 
process and results in a more complex understanding of the technology.
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Although the EU Council stated that “All health systems in the EU aim to make provision, 
which is patient-centered and responsive to individual need”, unacceptable differences in 
access to orphan medicinal products (OMP) in the Member States of the European 
Union are identified. In the context of the 2010 Belgian EU presidency initiative 
on ‘Innovation and Solidarity’ and within the framework of the process on corpo-
rate responsibility in the field of pharmaceuticals, EU Commissioner Tajani there-
fore launched the project Mechanism of Coordinated Access to OMP.Objectives: 
Designing a operational mechanism of coordinated access to OMP for patients, stake-
holders and Member States to provide, irrespective of the local conditions, access for 
patients with unmet medical needs and for whom these solutions would otherwise 
be out of reach – in an affordable and sustainable way (“real life access”). MethOds: 
The project is managed by Belgium (NIHDI), supported by the European Commission 
and Eminet. Thirteen Member States participated, with the stakeholders (AIM, EPF, 
ESIP, Eurordis, CPME, EFPIA, EGA, EuropaBio, GIRP). Three Workpackages cover the 
different aspects of granting effective access to medicines: Identifying and assess-
ing a relevant orphan drug (assessment/evaluation) - Selection of target population 
and mechanisms of funding (structural access) - Treatment (individual access). 
Feasibility at present and opportunities for near future development of desirable 
activities were studied, and no-go solutions were documented and rejected in order 
to develop implementable scenarios for pilot projects and policy recommendations. 
Discussion: Although coordinated access at an European level will be organized on a 
voluntary basis, some sort of commitment from the participating partners is required. 
Moreover, it is crucial that the subsidiarity principle is not jeopardized or compro-
mised. Duplication of efforts will be avoided and previously made investments – in 
terms of financial and human resources, expertise and experience - (ex. by EUnet 
HTA, EMA COMP, EUCERD, CAVOD,…) will be valorized.
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Objectives: To look at the affordability of orphan medications across Europe and 
whether payer attitudes to high-price medications are changing in the face of ris-
ing health care expenditure and tighter budgets. MethOds: A detailed review of 
7 EU markets (France, Germany, Italy, The Netherlands, Poland, Spain, UK) looking 
at payer attitudes and funding decisions for key orphan drugs and the political, 
economic and societal impact of these. A key focus of the research was insight into 
payer attitudes towards the evidence base for the purpose of pricing negotiations 
and how anecdotal evidence, such as Patient Reported Outcomes (PROs) and patient 
case studies, have an impact on decision-making. Detailed research was also under-
taken to ascertain the pricing levels achieved for a number of orphan drugs across 
Europe looking at payer thresholds and the implications of these for the purpose 
of reimbursement. Results: The research demonstrates that there is considerable 
variation in pricing levels across the European markets and difference in payer 
attitudes towards the way orphan drugs are funded. Overcoming evidence chal-
lenges in orphan diseases remains a headache for payers and scepticism remains 
around dosing, innovation and whether approaches such as “coverage with evidence 
development” are adequate and/or sustainable in the long-term following initial 
approval. cOnclusiOns: The environment for orphan medicines in Europe is 
changing; and as the financial performance of European countries begins to diverge, 
so do attitudes towards the funding of orphan medicines. Orphan medicine prices 
are rarely justified on the basis of traditional cost-effectiveness thresholds and most 
markets still differentiate them from other pharmaceuticals. However, payers are 
afraid of uncertainty and, given the increasing number of orphan drugs and the 
often tentative evidence base at launch, may be forced by overwhelming financial 
necessity to make tougher decisions on funding.
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Decision making rules in health technology assessments are often based on a fixed 
willingness to pay threshold for the incremental cost effectiveness. This may be 
thought of as consistent with expected utility – with utility here defined in terms of 
Incremental Net Benefit (INB) – a combination of QALY gain and the threshold value. 
Alternative methods such as multi criteria decision analysis allow incorporation 
of other dimensions into the decision space. These seek to explore whether utility 
may be driven by factors other than simple QALY gain. Prospect theory suggests 
that decision makers are concerned in practice with the ‘size’ of a given decision. 
Also, they handle investment and disinvestment differently. In the Irish State, every 
new drug is examined. In order to look at actual decisions, lifetime QALY gains were 
extracted from completed economic evaluations submitted to the Irish health care 
payer. Total spend on these was calculated using a combination of the payer reim-
bursement database and predicted budget impact. Real choices indicate that where 
the budget impact is relatively small the drug is more likely to be reimbursed even 
with a comparatively small QALY gain. Technologies in areas of cancer and orphan 
diseases often lie outside of the threshold where a technology would be accepted. 
Decision makers are faced with choices with varying degrees of risk. Choices asso-
ciated with a low budget impact are deemed to be less risky. This is pragmatic; it 
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sure by demanding early decisions and rapid access. Decision makers may unduly 
delay potential benefits to patients by waiting for stronger evidence, or may endorse 
medicines that later turn out to have a less robust benefit-risk ratio, to be ineffective, 
cost-ineffective, or even harmful. Hence, many countries have developed mechanisms 
that allow temporary access to promising medicines while concurrently requesting the 
generation of additional evidence to reduce uncertainty. Their objective is an optimal 
trade-off between different stakeholder needs, flexibility, responsiveness, and rigor as 
well as the flexibility to revise decisions on access when new evidence becomes avail-
able. The ENCePP WG on HTA has the potential to become a capacity building tool for 
regulatory and HTA agencies to develop research structures aimed at complementing 
the evidence generation for MA and market access. Post-authorisation studies devel-
oped under the auspices of ENCePP could provide new safety and clinical effectiveness 
information of marketed medicines. ENCePP expertise, research experience and health 
care databases may also contribute to the coordination, methodological guidance and 
data sourcing for the enhancement of HTA processes.
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Objectives: Main function of a health system is to prevent diseases, restore health 
status and reduce health impairment. Health systems are mainly organized on effi-
cacy based decisions, but sometimes their social functions modulate this principle. 
In case of small patient groups, end-stage status and unmet health needs, usually 
decision are made on the basis of equity, instead of efficacy. These demands create 
special development conditions; eventuate in high prices on the supply side, therefore 
cost-effectiveness cannot be guaranteed, not even with substantial health benefits. 
Numerous expensive drug therapies are available in Hungary with reimbursement, 
but due to fiscal restrictions, new therapies are not able to access reimbursement. 
These tendencies create a paradox situation, since equity is implemented occasionally 
in absence of objective criteria. Due to the huge differences among these therapies, a 
standardized decision-making principle does not exist, but a general framework can 
be developed. In our study, methods and techniques are introduced, which can help to 
assess these therapies and organize a transparent system. MethOds: For the general 
assessment of therapies, many methods are available. In our research, we reviewed 
these tools and investigated their combinability in the special situation of “high-
value” therapies. Results: A wide range of evidences (clinical trials, meta-analysis, 
health-economy analysis, HTAs) provide a robust background to compare high-value 
therapies between different therapeutic areas. Outputs (LYG, OS, QALY, costs etc.) 
show a significant variation following different clarification process. A standard-
ized process needed to earn comparable outputs from evidences. cOnclusiOns: As 
we found, these tools could help decision making on prioritizing therapies, allocate 
resources with a higher control and reduce the risk of reimbursement.
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Orphan Drug Legislation incentivises the development of treatments for rare dis-
eases that would otherwise not be profitable investment opportunities. However, 
with budgets squeezed and diseases increasingly stratified, we question whether 
this legislation is fit for purpose. Segmenting diseases into genetically-defined sub-
groups, most notably among some cancers, has enabled increased pharmacological 
targeting. Common diseases are thus being reconsidered as multiple rare conditions, 
each eligible for orphan designation, entitling the treatments to the economic ben-
efits afforded by legislation. Stratification also occurs in diseases which are already 
rare (e.g. cystic fibrosis), and new treatments, such as ivacaftor, are being developed 
to target specific mutations. Orphan status for a drug is maintained regardless of 
whether the overall population size, for which the drug is licensed, exceeds prevalence 
thresholds enabling companies to take a strategic approach to development. The high 
prices of orphan drugs impact on access. However, typical cost-effectiveness thresh-
olds are often waived suggesting that greater value is placed on treatments for rare 
conditions, compared with prevalent diseases that are equally severe and debilitating. 
Population surveys indicate that funding policies that take resources from elsewhere 
in health economy budgets to fund these treatments are not in the public interest. 
At the same time, research and development into certain common diseases such as 
stroke, where the burden is much higher, has been somewhat neglected. We believe 
it is time to revisit orphan drug legislation. Regulators should be able to limit the 
benefits of orphan designation should the cumulative eligible population exceed a 
certain threshold. More robust criteria need to be applied for defining a “medically 
plausible subset” and pricing should to be brought closer in line with drugs for non-
rare diseases. Furthermore, the focus of incentives should move more towards areas 
of unmet need where disease burden is greatest.
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In this paper, we review a well-known phenomenon of »me-too« drugs in the pharma-
ceutical branded markets, which has gained wide attention during the recent years. 
A branded “me-too” drug is deemed having somewhat similar therapeutic effect as 
the “breakthrough” drug, although from an intellectual property right perspective, 
there is no difference between the two. Definition of “me-too” drugs has yet to reach 
consensus and it would likely be ferociously disputed by the branded firms. When the 
first branded »me-too« drug enters the market, we are dealing with oligopoly, or more 
precisely, duopoly, described by Cournot model. From an oligopoly model, we would 
expect at Nash equilibrium both price to decrease and total volume to increase com-
pared to shared monopoly conditions. An oligopolistic structure of a »me-too« phar-
maceutical market puts substantial emphasis on branding and promotion (to achieve 
Objective: Pharmaceutical pricing is characterized by a consistent variability across 
markets. Social and economic differences represent only the easiest-to-predict reason 
for such variability. Stricter regulatory hurdles, market landscape, challenging nego-
tiation processes, varying business strategies, and sometimes unplanned outcomes 
of pharma launch decisions concur in the final price for a specific drug. A better 
understanding of price trends and out-patterns is a useful insight to help improving 
pricing strategies by targeting realistic pricing expectations, and studying competi-
tors’ pricing mistakes and successes. This paper shows the price variability of ten 
different pharmaceuticals in ten key markets (France, Germany, UK, Italy, Spain, US, 
Brazil, Russia, India, and China). Common trends, similarities and particularities are 
discussed. MethOds: Using PRICENTRICTM data, we collected ex-factory prices for 
various oncology products, and we defined whether a country fell into a HTA sys-
tem or free pricing group. We also compared the product prices to GDP per capita 
(International Monetary Fund 2012) to investigate trends between the two parameters. 
The analysis investigates two key areas: 1. Difference in price depends on social, eco-
nomic considerations but also by the nature and complexity of market access process 
2. The relationship between prices and GDP per capita across countries. Results: The 
US and Germany have the highest prices of all studied countries. They are also the 
only two countries where prices are freely set by manufacturers. Prices are slightly 
higher in countries having a high GDP per capita. However, countries like France and 
UK having strong HTA authorities and pricing regulations do have a small correlation 
to this trend line. cOnclusiOn: Our analysis shows that pricing and pharma strate-
gies can be based on countries’ economic situation. Nevertheless, formal established 
HTA bodies with clear pricing rules help controlling pricing.
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Collaboration with health care stakeholders is a fundamental component of a sys-
tems-based health care economy, and it will become the dominate business model 
going forward. Yet most health care industry stakeholders are failing to accept this 
inevitable transition. While many acknowledge the need to move toward a more 
integrated “systems thinking” approach – one that maps influence patterns, ampli-
fies interdependencies, and drives collective outcomes, they struggle with actual 
implementation. A viable and sustainable information network provides the struc-
ture, aligned incentives and competitive collaboration the bricks and mortar, and 
trust the cornerstone. Until they can build that and foster a culture of transparency, 
they won’t achieve the cost and innovation benefits inherent in these cross-industry 
partnerships. Although health care stakeholders know they need to partner with 
others to be successful in this new systems-thinking economy, they need actionable 
strategies to demonstrate how the benefits of ongoing collaborations far outweigh 
the risks. This podium presentation will present original research aimed to qualify 
stakeholder perceptions on alignment and collaboration around the delivery of health 
care, in addition to critical hurdles they must overcome. A recent survey of close to 
300 Biopharma executives, EU and US Payers, and US providers provides insight into 
their needs, their disparate perceptions, and their levels of confidence in the ability to 
shift to a systems-thinking collaborative culture. Approximately 25% of respondents 
stated they were not aligned with other stakeholders, though agree they need better 
alignment and foresee closer collaboration in the future. Over 70% of stakeholders 
believe data transparency and information-sharing is critically important to a suc-
cessful and interoperable health care system, yet very few from each group were 
willing to demonstrate such transparency. Further detail will be given on insights and 
challenges gleaned from interviewing large and small stakeholders as well as practical 
strategies to guide the transformation to a systems-thinking industry.
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The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP) is a project led by the European Medicines Agency aimed at further strength-
ening the post-authorisation monitoring of medicinal products in Europe by facilitat-
ing the conduct of multi-centre, independent post-authorisation studies focusing on 
safety and benefit/risk assessment. ENCePP has recently established a WG on HTA 
to develop methodological guidance to supplement the efficacy and safety aspects 
of medicines known at the time of marketing authorisation (MA) and to bridge the 
needs of HTA and post-marketing benefit-risk assessments. Decision makers are often 
faced with the challenge that long-term, real-world data on safety and effectiveness is 
lacking at the time of MA. This creates uncertainty around the medicines’ risk-benefit 
profile while manufacturers, health care providers, and patient groups exert pres-
